Top Headlines

Reimportation is “legislative madness”

It is “legislative madness” to allow reimportation in the US, according to the chair of EAASM who spoke at AAPS about Europe’s “porous supply chain” and how it could affect the standard of medicines in the States.

Vaccine demand a friend to Pall in Q1; but sales still fall 5.4%

Continued high demand for vaccine manufacturing technologies saw life sciences emerge as one of the few positives for industrial processing specialist Pall in Q1.

People on the move: pharma jobs

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Xoma and Watson Pharmaceuticals, plus a new role for Fred Hasaan.

Reaxa gets UK grant for Ni EnCat scale-up

UK process technologies firm Reaxa has received a £146K (€164K) R&D grant from the Northwest Regional Development Agency (NWDA) to scale-up production of its EnCat nickel catalyst.

BASF talks novel excipients

The FDA encourages innovation in excipients to develop new drugs or improve approved therapeutics and IPEC is helping to drive acceptance of these novel products, according to BASF.

News in brief

Today's headlines across the Pharmaceutical industry

PPD targets NJ, PA from Outsourcing-Pharma.com

PPD’s acquisition of Merck’s vaccine testing laboratory will give it a geographic location from which it can compete for business with its “number one competitor”, which is well established in the north east of the US.

Further boost for Covance’s biomarker offering in RBM deal from Outsourcing-Pharma.com

Covance will outsource biomarker activities to US laboratory group Rules-Based Medicine (RBM) in an exclusive deal announced yesterday.

eClinical definition is changing; SVP from Outsourcing-Pharma.com

Phase Forward is moving towards offering integrated systems to meet pharma’s need to maximise cost effectiveness and deal with upcoming EDC market saturation, according to a SVP at the company.

Work needed to close gender knowledge gap from Outsourcing-Pharma.com

Regulators, industry and academia must do more to close the knowledge gap created by a historic shortage of women in clinical trials, according to speakers at AAPS 2009.

On your radar